Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/46293
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKarimnia N.-
dc.contributor.authorWilson A.L.-
dc.contributor.authorGreen E.-
dc.contributor.authorMatthews A.-
dc.contributor.authorJobling T.W.-
dc.contributor.authorPlebanski M.-
dc.contributor.authorBilandzic M.-
dc.contributor.authorStephens A.N.-
dc.date.accessioned2022-02-10T23:55:53Z-
dc.date.available2022-02-10T23:55:53Z-
dc.date.copyright2021-
dc.date.issued2021-09-10en
dc.identifier.citationJournal of Experimental and Clinical Cancer Research. 40(1) (no pagination), 2021. Article Number: 276. Date of Publication: December 2021.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/46293-
dc.description.abstractBackground: Leader cells are a subset of cancer cells that coordinate the complex cell-cell and cell-matrix interactions required for ovarian cancer migration, invasion, tumour deposition and are negatively associated with progression-free survival and response to therapy. Emerging evidence suggests leader cells may be enriched in response to chemotherapy, underlying disease recurrence following treatment. Method(s): CRISPR was used to insert a bicistronic T2A-GFP cassette under the native KRT14 (leader cell) promoter. 2D and 3D drug screens were completed in the presence of chemotherapies used in ovarian cancer management. Leader cell; proliferative (Ki67); and apoptotic status (Cleaved Caspase 3) were defined by live cell imaging and flow cytometry. Quantitative real-time PCR defined "stemness" profiles. Proliferation was assessed on the xCELLigence real time cell analyser. Statistical Analysis was performed using unpaired non-parametric t-tests or one-way ANOVA and Tukey's multiple comparison post hoc. Result(s): Leader cells represent a transcriptionally plastic subpopulation of ovarian cancer cells that arise independently of cell division or DNA replication, and exhibit a "stemness" profile that does not correlate with epithelial-to-mesenchymal transition. Chemotherapeutics increased apoptosis-resistant leader cells in vitro, who retained motility and expressed known chemo-resistance markers including ALDH1, Twist and CD44v6. Functional impairment of leader cells restored chemosensitivity, with leader cell-deficient lines failing to recover following chemotherapeutic intervention. Conclusion(s): Our data demonstrate that ovarian cancer leader cells are resistant to a diverse array of chemotherapeutic agents, and are likely to play a critical role in the recurrence of chemo-resistant disease as drivers of poor treatment outcomes.Copyright © 2021, The Author(s).-
dc.publisherBioMed Central Ltd-
dc.relation.ispartofJournal of Experimental and Clinical Cancer Research-
dc.subject.meshanalysis of variance-
dc.subject.meshapoptosis-
dc.subject.mesh*cancer cell-
dc.subject.meshcancer recurrence-
dc.subject.meshcancer stem cell-
dc.subject.meshcell division-
dc.subject.meshcell motility-
dc.subject.meshcell proliferation-
dc.subject.meshcell selection-
dc.subject.meshcell subpopulation-
dc.subject.meshcell viability-
dc.subject.meshchemosensitivity-
dc.subject.meshclustered regularly interspaced short palindromic repeat-
dc.subject.meshcorrelation analysis-
dc.subject.meshDNA replication-
dc.subject.meshdrug screening-
dc.subject.meshenzyme degradation-
dc.subject.meshepithelial mesenchymal transition-
dc.subject.meshflow cytometry-
dc.subject.meshIC50-
dc.subject.meshin vitro study-
dc.subject.meshlive cell imaging-
dc.subject.meshnonparametric test-
dc.subject.mesh*ovary cancer/dr [Drug Resistance]-
dc.subject.meshpost hoc analysis-
dc.subject.meshpromoter region-
dc.subject.meshprotein expression-
dc.subject.meshreal time polymerase chain reaction-
dc.subject.meshtreatment outcome-
dc.subject.meshaldehyde dehydrogenase isoenzyme 1/ec [Endogenous Compound]-
dc.subject.mesh*antineoplastic agent-
dc.subject.meshcarboplatin/pd [Pharmacology]-
dc.subject.meshcaspase 3/ec [Endogenous Compound]-
dc.subject.meshCD133 antigen/ec [Endogenous Compound]-
dc.subject.meshCD44v6 antigen/ec [Endogenous Compound]-
dc.subject.meshcisplatin/pd [Pharmacology]-
dc.subject.meshcyclophosphamide/pd [Pharmacology]-
dc.subject.meshcytokeratin 14/ec [Endogenous Compound]-
dc.subject.meshDNA/ec [Endogenous Compound]-
dc.subject.meshdoxorubicin/pd [Pharmacology]-
dc.subject.meshepithelial cell adhesion molecule/ec [Endogenous Compound]-
dc.subject.meshfibronectin/ec [Endogenous Compound]-
dc.subject.meshgreen fluorescent protein-
dc.subject.meshKi 67 antigen/ec [Endogenous Compound]-
dc.subject.meshnerve cell adhesion molecule/ec [Endogenous Compound]-
dc.subject.meshNotch receptor/ec [Endogenous Compound]-
dc.subject.meshoctamer transcription factor 4/ec [Endogenous Compound]-
dc.subject.mesholaparib/pd [Pharmacology]-
dc.subject.meshpaclitaxel/pd [Pharmacology]-
dc.subject.meshrucaparib/pd [Pharmacology]-
dc.subject.meshstem cell factor receptor/ec [Endogenous Compound]-
dc.subject.meshtopotecan/pd [Pharmacology]-
dc.subject.meshtranscription factor NANOG/ec [Endogenous Compound]-
dc.subject.meshtranscription factor Slug/ec [Endogenous Compound]-
dc.subject.meshtranscription factor Snail/ec [Endogenous Compound]-
dc.subject.meshtranscription factor Twist/ec [Endogenous Compound]-
dc.subject.meshuvomorulin/ec [Endogenous Compound]-
dc.subject.meshvimentin/ec [Endogenous Compound]-
dc.subject.meshWnt1 protein/ec [Endogenous Compound]-
dc.subject.mesh*leader cell-
dc.titleChemoresistance is mediated by ovarian cancer leader cells in vitro.-
dc.typeArticle-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1186/s13046-021-02086-3-
dc.publisher.placeUnited Kingdom-
dc.identifier.pubmedid34470672 [http://www.ncbi.nlm.nih.gov/pubmed/?term=34470672]-
dc.identifier.institution(Jobling) Monash Medical Centre, Department of Gynaecology Oncology, Monash Health, Moorabbin, Australiaen
dc.identifier.institution(Karimnia, Wilson, Green, Matthews, Bilandzic, Stephens) Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC 3168, Australiaen
dc.identifier.institution(Green, Matthews) Department of Molecular and Translational Sciences, Monash University, Clayton, Australiaen
dc.identifier.institution(Plebanski) School of Health and Biomedical Sciences, RMIT University, Bundoora, Australiaen
dc.subect.keywordsarticle-
dc.subect.keywordscontrolled study-
dc.subect.keywordshuman-
dc.subect.keywordshuman cell-
dc.subect.keywordshuman tissue-
dc.identifier.affiliationext(Karimnia, Wilson, Green, Matthews, Bilandzic, Stephens) Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC 3168, Australia-
dc.identifier.affiliationext(Green, Matthews) Department of Molecular and Translational Sciences, Monash University, Clayton, Australia-
dc.identifier.affiliationext(Plebanski) School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia-
dc.identifier.affiliationmh(Jobling) Monash Medical Centre, Department of Gynaecology Oncology, Monash Health, Moorabbin, Australia-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptObstetrics and Gynaecology (Monash Women's)-
Appears in Collections:Articles
Show simple item record

Page view(s)

20
checked on Apr 3, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.